Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
04:30pm, Friday, 07'th Nov 2025
Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Proces
Cellectis to Present a Development Update for eti-cel at ASH 2025
09:15am, Monday, 03'rd Nov 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis to Report Third Quarter Financial Results on November 7, 2025
04:30pm, Friday, 31'st Oct 2025
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to d
○ Efficacité: taux de réponse global (ORR) de 68 % avec le Process 2 de lasmé-cel (P2) (n=22); 83 % à la dose recommandée de Phase 2 (RP2D, n=12); et 100 % dans la population cible de Phase 2 (
Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL
03:19pm, Thursday, 16'th Oct 2025
○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)
Top 2 Health Care Stocks That May Keep You Up At Night This Month
08:46am, Thursday, 16'th Oct 2025
As of Oct. 16, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
07:00am, Thursday, 16'th Oct 2025
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
02:40am, Tuesday, 07'th Oct 2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript
11:50am, Tuesday, 05'th Aug 2025
Cellectis S.A. (NASDAQ:CLLS ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Adrian Kilcoyne - Chief Medical Officer Andre Choulika - Co-Founder, CEO & Director Arthur
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
04:30pm, Monday, 04'th Aug 2025
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
04:30pm, Monday, 28'th Jul 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to d
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
04:30pm, Thursday, 26'th Jun 2025
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c
Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025
04:30pm, Wednesday, 21'st May 2025
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to d
Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy
10:58am, Thursday, 15'th May 2025
Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further by a
Cellectis Reports Financial Results for the First Quarter 2025
04:30pm, Monday, 12'th May 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to d
